UNICREDIT BANK/CALL/ELI LILLY & CO/1300/0.1/17.06.26 | Market Closed - BOERSE MUENCHEN 03:41:30 2024-05-23 pm EDT | ||
| 5.07 EUR | +5.41% |
|
| Current month | +11.18% | ||
| 1 month | +33.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 5.07 | +5.41% |
| 24-05-22 | 4.81 | -1.43% |
| 24-05-21 | 4.88 | +14.29% |
| 24-05-20 | 4.27 | +4.40% |
| 24-05-17 | 4.09 | -2.62% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4LBU |
| ISIN | DE000HD4LBU2 |
| Date issued | 2024-04-12 |
| Strike | 1,300 $ |
| Maturity | 2026-06-17 (755 Days) |
| Parity | 10 : 1 |
| Emission price | 4.74 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.07 € |
|---|---|
| Lowest since issue | 3.41 € |
| Spread | 0.52 € |
| Spread % | 9.47% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
808.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.24%
- Stock Market
- Warrants
- Warrant
